Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Keros potential drug for high blood pressure in lungs KER-012 shows tolerability in healthy people in interim data | - | Seeking Alpha | ||
Mi | Keros Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
KEROS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Mi | Keros Therapeutics, Inc.: Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy ... | - | GlobeNewswire (USA) | ||
Di | Keros Therapeutics, Inc.: Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American ... | 1 | GlobeNewswire (USA) | ||
12.05. | Keros Therapeutics, Inc.: Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association | 1 | GlobeNewswire (USA) | ||
05.05. | Keros Therapeutics GAAP EPS of -$1.01 misses by $0.15 | - | Seeking Alpha | ||
05.05. | Keros Therapeutics, Inc. - 10-Q, Quaterly Report | 1 | SEC Filings | ||
05.05. | Keros Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
25.04. | Klüh gründet Keros für nachhaltige und digitale Prozessoptimierung | - | DEAL-Magazin | ||
09.03. | Keros Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
09.03. | Keros Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
09.03. | Keros Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.03. | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results | 1 | GlobeNewswire (USA) | ||
11.02. | Keros Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
11.02. | Keros Therapeutics, Inc.: Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference | - | GlobeNewswire (USA) | ||
31.01. | Keros Therapeutics appoints Rovaldi as COO | - | Seeking Alpha | ||
31.01. | Keros Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
15.12.21 | Keros gives Hansoh subsidiary license for lead drug in $190M+ deal; Vaccitech snaps up new tools in small buyout | 1 | Endpoints News | ||
13.12.21 | Keros Therapeutics, Inc.: Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical ... | 1 | GlobeNewswire (USA) | ||
13.12.21 | Keros Therapeutics inks licensing deal for KER-050 in China | - | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 42,730 | +1,04 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Berenberg hat die Einstufung für Qiagen nach einer Konferenz der Privatbank auf "Buy" mit einem Kursziel von 50 Euro belassen. Die Nachfrage nach Diagnose-Technologie dürfte... ► Artikel lesen | |
AMGEN | 233,60 | -0,28 % | Dividendenbekanntmachungen (16.05.2022) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANSIX INC US00773T1016 0,125 USD 0,12 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6393 EUR AIR LIQUIDE SA FR0000120073 - 2,9... ► Artikel lesen | |
BIOGEN | 185,84 | -1,73 % | BIOGEN INC. - S-4, Registration of securities, business combinations | ||
ILLUMINA | 225,20 | -2,41 % | Allegheny Health Network taps Illumina to research in-house cancer genomic profiling for patients | ||
REGENERON PHARMACEUTICALS | 623,90 | -0,38 % | FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule | ||
SANGAMO THERAPEUTICS | 3,880 | +3,87 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation... ► Artikel lesen | |
ABIOMED | 219,00 | -2,01 % | Kurs von Abiomed fällt ab | Die Aktie von Abiomed notiert heute etwas leichter. Das Papier notiert zur Stunde bei 225,40 Euro. Ein Verlust von 0,75 Prozent steht gegenwärtig für das Wertpapier von Abiomed zu Buche. Das Wertpapier... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 5,200 | -2,24 % | PACB, JAMF and PRVB are among after hour movers | ||
MYRIAD GENETICS | 20,320 | -2,45 % | Myriad Genetics Inc. Q1 Loss Increases, but beats estimates | WASHINGTON (dpa-AFX) - Myriad Genetics Inc. (MYGN) released Loss for first quarter that decreased from the same period last year but missed the Street estimates.The company's bottom line came... ► Artikel lesen | |
IDEXX LABORATORIES | 344,55 | +1,47 % | Die IDEXX Laboratories-Aktie läuft schlechter: Große Kursverluste! | Zu den großen Verlierern an der Börse zählt heute das Wertpapier von IDEXX Laboratories . Das Wertpapier verliert deutlich an Wert. Ein Kurssturz von 4,91 Prozent zeigt die Kurstafel für die Aktie von... ► Artikel lesen | |
REPLIGEN | 143,68 | -1,88 % | Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand? | ||
ABCELLERA BIOLOGICS | 7,303 | -2,47 % | Why AbCellera Biologics Is 10% Lower Today | ||
EMERGENT BIOSOLUTIONS | 33,200 | -0,84 % | Why Emergent BioSciences Stock Is Soaring Today | ||
SIGA TECHNOLOGIES | 12,400 | +43,35 % | SIGA Technologies - IV TPOXX receives FDA Approval | SIGA Technologies announced the FDA approval for its intravenous (IV) formulation of tecovirimat (TPOXX), an antiviral drug for the treatment of smallpox. We had already anticipated that approval was... ► Artikel lesen | |
BIONTECH | 154,85 | +0,23 % | BioNTech Aktie: Reden wir drüber - über Alles ausser Comirnaty - Medigene, Crescendo Biologics, Matinas - dazu "massenhaft" klinische Studien | Biontech - Aktie die sich grossen Interesses von Privatanlegern erfreut oder muss man sagen erfreute? Mit überraschend starken Quartalsergebnissen überraschten die Mainzer viele - und schlugen alle... ► Artikel lesen |